TOPOLOGY: A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer

被引：0
|
作者：
Cabel, Luc
Loirat, Delphine
Babau, Jerome Martin
Bello, Diana
Pierga, Jean-Yves
Lerebours, Florence
Ezzili, Cyrine
Berger, Frederique
Bidard, Francois Clement
机构：
[1] Inst Curie, Paris, France
[2] Inst Curie, St Cloud, France
[3] Inst Curie, Med Oncol Dept & D3i, Paris, France
[4] Hop Prive Cotes Armor, Plerin, France
[5] Inst Curie, Med Oncol Dept, St Cloud, France
[6] Inst Curie Paris, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1142
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy of biological agents in metastatic triple-negative breast cancer
    Bramati, Annalisa
    Girelli, Serena
    Torri, Valter
    Farina, Gabriella
    Galfrascoli, Elena
    Piva, Sheila
    Moretti, Anna
    Dazzani, Maria Chiara
    Sburlati, Paola
    La Verde, Nicla Maria
    CANCER TREATMENT REVIEWS, 2014, 40 (05) : 605 - 613
  • [22] Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
    Colt A. Egelston
    Weihua Guo
    Susan E. Yost
    Xuan Ge
    Jin Sun Lee
    Paul H. Frankel
    Yujie Cui
    Christopher Ruel
    Daniel Schmolze
    Mireya Murga
    Aileen Tang
    Norma Martinez
    Misagh Karimi
    George Somlo
    Peter P. Lee
    James R. Waisman
    Yuan Yuan
    Cancer Immunology, Immunotherapy, 2023, 72 : 3013 - 3027
  • [23] Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
    Egelston, Colt A.
    Guo, Weihua
    Yost, Susan E.
    Ge, Xuan
    Lee, Jin Sun
    Frankel, Paul H.
    Cui, Yujie
    Ruel, Christopher
    Schmolze, Daniel
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Karimi, Misagh
    Somlo, George
    Lee, Peter P.
    Waisman, James R.
    Yuan, Yuan
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (09) : 3013 - 3027
  • [24] Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study
    Tan, Antoinette R.
    Wright, Gail S.
    Thummala, Anu R.
    Danso, Michael A.
    Popovic, Lazar
    Pluard, Timothy J.
    Han, Hyo S.
    Vojnovic, Zeljko
    Vasev, Nikola
    Ma, Ling
    Richards, Donald A.
    Wilks, Sharon T.
    Milenkovic, Dusan
    Xiao, Jie
    Sorrentino, Jessica
    Horton, Janet
    O'Shaughnessy, Joyce
    CLINICAL CANCER RESEARCH, 2022, 28 (04) : 629 - 636
  • [25] A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer
    Clinton Yam
    Gaiane M. Rauch
    Tanbin Rahman
    Meghan Karuturi
    Elizabeth Ravenberg
    Jason White
    Alyson Clayborn
    Pamela McCarthy
    Sausan Abouharb
    Bora Lim
    Jennifer K. Litton
    David L. Ramirez
    Sadia Saleem
    James Stec
    W. Fraser Symmans
    Lei Huo
    Senthil Damodaran
    Ryan Sun
    Stacy L. Moulder
    Investigational New Drugs, 2021, 39 : 509 - 515
  • [26] A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer
    Yam, Clinton
    Rauch, Gaiane M.
    Rahman, Tanbin
    Karuturi, Meghan
    Ravenberg, Elizabeth
    White, Jason
    Clayborn, Alyson
    McCarthy, Pamela
    Abouharb, Sausan
    Lim, Bora
    Litton, Jennifer K.
    Ramirez, David L.
    Saleem, Sadia
    Stec, James
    Symmans, W. Fraser
    Huo, Lei
    Damodaran, Senthil
    Sun, Ryan
    Moulder, Stacy L.
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (02) : 509 - 515
  • [27] Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
    Tolaney, Sara M.
    Kalinsky, Kevin
    Kaklamani, Virginia G.
    D'Adamo, David R.
    Aktan, Gursel
    Tsai, Michaela L.
    O'Regan, Ruth M.
    Kaufman, Peter A.
    Wilks, Sharon T.
    Andreopoulou, Eleni
    Patt, Debra A.
    Yuan, Yuan
    Wang, Grace
    Savulsky, Claudio
    Xing, Dongyuan
    Kleynerman, Ella
    Karantza, Vassiliki
    Diab, Sami
    CLINICAL CANCER RESEARCH, 2021, 27 (11) : 3061 - 3068
  • [28] Phase II trial of RAMO I plus carhoplatin in patients with triple-negative metastatic breast cancer
    Singh, J. C.
    Stein, S.
    Volm, M.
    Smith, J. A.
    Novik, Y.
    Speyer, J. L.
    Adams, S.
    Meyers, M. I.
    Muggia, F.
    Schneider, R.
    Formenti, S.
    Davis, S.
    Choi, H.
    Tiersten, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [29] A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes
    Li, Qiao
    Li, Qing
    Zhang, Pin
    Yuan, Peng
    Wang, Jiayu
    Ma, Fei
    Luo, Yang
    Fan, Ying
    Cai, Ruigang
    Xu, Binghe
    CANCER BIOLOGY & THERAPY, 2015, 16 (12) : 1746 - 1753
  • [30] A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes
    Li, Qiao
    Xu, Binghe
    Li, Qing
    Zhang, Pin
    Yuan, Peng
    Wang, Jiayu
    Ma, Fei
    Luo, Yang
    Fan, Ying
    Cai, Ruigang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345